Firivumab Antibody is a research-grade biosimilar monoclonal antibody targeting HA/Hemagglutinin. It is a human IgG1, kappa antibody. Reactivity: Influenza A virus (H1, H2, H5, H9 subtype). Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Hemagglutinin (HA) is a ~63 kDa protein. Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization of about two third of the virus particles through clathrin-dependent endocytosis and about one third through a clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane.
Product Name:
Firivumab Antibody
SKU:
GXBS00504
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
HA
Isotype:
IgG1, kappa
Host Species:
Human
Reactivity:
Influenza A virus (H1, H2, H5, H9 subtype)
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
CT-P22, 1443004-15-6
Recommended Dilutions:
ELISA: 1:2000-1:20000
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
